Virtua Research for Cardiology

< Back

Status: Enrolling

02-013

JOSTENT/GRAFTMASTER - The GraftMaster® RX Coronary Stent Graft System is approved under a Humanitarian Device Exemption (HDE) only for the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts = 2.75 mm in diameter.

The GraftMaster® RX Coronary Stent Graft System is approved under a
Humanitarian Device Exemption (HDE) only for the treatment of free
perforations, defined as free contrast extravasation into the pericardium, in
native coronary vessels or saphenous vein bypass grafts = 2.75 mm in
diameter.

Principle Investigator: Anthony Smeglin, M.D.

Contact for Participation in this study:
Danielle Connors
Research Assistant
856-635-2674
dconnors@virtua.org

Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
 

Status: Enrolling

20170418

HF-OPT Registry - The manufacturer (ZOLL) is sponsoring a study to collect medical information during WCD use and up to one year after the start of WCD.

The manufacturer (ZOLL) is sponsoring a study to collect medical information during WCD use and up to one year after the start of WCD.

Principle Investigator: Robert Mohapatra, M.D.

Contact for Participation in this study:
Kristin Broderick
Research Assistant
856-673-1332
kbroderick@virtua.org

Office Location:
Virtua Cardiology Cherry Hill
1 Brace Road
Cherry Hill, NJ08034
 

Status: Enrolling

20170418

CONNECT-HF The purpose of this trial is to look at the outcome of two Heart failure quality improvement programs for patients with Heart failure up to 1 year post-discharge.

CONNECT-HF The purpose of this trial is to look at the outcome of two Heart failure quality improvement programs for patients with Heart failure up to 1 year post-discharge.

Principle Investigator: Robert Mohapatra, M.D.

Contact for Participation in this study:
Kristin Broderick
Research Assistant
856-673-1332
kbroderick@virtua.org

Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
 

Status: Enrolling

20170625

VESALIUS - Phase III Trial to test hypothesis that treatment with Evolocumab of patients at high cardiovascular risk, but without prior MI or stroke will reduce the risk of major cardiovascular events

VESALIUS - Phase III Trial to test hypothesis that treatment with Evolocumab of patients at high cardiovascular risk, but without prior MI or stroke will reduce the risk of major cardiovascular events

Principle Investigator: Richard Perlman, M.D., PhD

Contact for Participation in this study:
Donna Hoopes
Research Assistant
856-673-1354
dhoopes@virtua.org

Office Location:
Virtua Cardiology Voorhees
1105 Laurel Oak Road
Voorhees, NJ08043
 

Status: Enrolling

20172754

GUIDE HF - to demonstrate effectiveness of the CardioMEMS HF System in an expanded patient population including heart failure patients outside of the present indication, but at risk for future Heart failure events or mortality.

Principle Investigator: Robert Mohapatra, M.D.

Contact for Participation in this study:
Marisa Brown
Research Assistant
856-673-1346
mbrown3@virtua.org

Office Location:
Virtua Cardiology Cherry Hill
1 Brace Road
Cherry Hill, NJ08034
 

Status: Enrolling

20180259

AEGIS - Phase 3 study to investigate the Efficacy and Safety of CSL112 (Apolipoprotein) in subjects with ACS (STEMI/NSTEMI). Double blind, randomized with Albumin Placebo

AEGIS - Phase 3 study to investigate the Efficacy and Safety of CSL112 (Apolipoprotein) in subjects with ACS (STEMI/NSTEMI). Double blind, randomized with Albumin Placebo

Principle Investigator: Vijayendra Verma, M.D.

Contact for Participation in this study:
Donna Hoopes
Research Assistant
856-673-1354
dhoopes@virtua.org

Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
 

Status: Enrolling

20180815

SOLOIST - To demonstrate the Sotagliflozin reduces cardiovascular mortality compared to placebo in hemodynamically stable patients with type II diabetes and heart failure with a LV EF <50% after admission for worsening heart failure

SOLOIST - To demonstrate the Sotagliflozin reduces cardiovascular mortality compared to placebo in hemodynamically stable patients with type II diabetes and heart failure with a LV EF <50% after admission for worsening heart failure

Principle Investigator: Richard Perlman, M.D., PhD

Contact for Participation in this study:
Marisa Brown
Research Assistant
856-673-1346
mbrown3@virtua.org

Office Location:
Virtua Cardiology Voorhees
1105 Laurel Oak Road
Voorhees, NJ08043
 

Status: Enrolling

20190557

ASTELLAS - A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

A Phase 2 Proof of Concept, Double-blind, Randomized, Placebo controlled Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Principle Investigator: Arthur Martella, M.D.

Contact for Participation in this study:
Danielle Connors
Research Assistant
856-635-2674
dconnors@virtua.org

Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
 

Status: Enrolling

20190741

PARAGLIDE - 12 week study to evaluate the effect of Sacubatril/Valsartan (LCZ696/Entresto) versus Valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696/Entresto compared to Valsartan in HFpEF patients with acute decompensated heart failure

PARAGLIDE - 12 week study to evaluate the effect of Sacubatril/Valsartan (LCZ696/Entresto) versus Valsartan on changes in NT-proBNP and safety and tolerability of in-hospital initiation of LCZ696/Entresto compared to Valsartan in HFpEF patients with acute decompensated heart failure

Principle Investigator: Richard Perlman, M.D., PhD

Contact for Participation in this study:
Donna Hoopes
Research Assistant
856-673-1354
dhoopes@virtua.org

Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
 

Status: Enrolling

20192054

EV-ICD - The main purpose of the EV ICD Pivotal study is to demonstrate safety and efficacy of the EV ICD System. The Medtronic EV ICD System (defibrillator and lead) is indicated for the automated treatment of patients who have experienced, or are at significant risk of developing, life threatening ventricular tachy-arrhythmias.

EV-ICD - The main purpose of the EV ICD Pivotal study is to demonstrate safety and efficacy of the EV ICD System. The Medtronic EV ICD System (defibrillator and lead) is indicated for the automated treatment of patients who have experienced, or are at significant risk of developing, life threatening ventricular tachy-arrhythmias.

Principle Investigator: Darius Sholevar, M.D.

Contact for Participation in this study:
Danielle Connors
Research Assistant
856-635-2674
dconnors@virtua.org

Office Location:
Virtua Health Our Lady of Lourdes
1600 Haddon Ave
Camden, NJ08103
 

Status: Enrolling

Pro 00034564

ORION Double blind, Randomized, Placebo-Controlled trial Assessing the Effects of Inclisiran on Clinical Outcomes Among people with Atherosclerotic Cardiovascular Disease

ORION Double blind, Randomized, Placebo-Controlled trial Assessing the Effects of Inclisiran on Clinical Outcomes Among people with Atherosclerotic Cardiovascular Disease

Principle Investigator: Richard Perlman, M.D., PhD

Contact for Participation in this study:
Kristin Broderick
Research Assistant
856-673-1332
kbroderick@virtua.org

Office Location:
Virtua Cardiology Voorhees
1105 Laurel Oak Road
Voorhees, NJ08043
 

Status: Enrolling

Pro 00037778

BMAD TX - Benefits of uCor in Ambulatory Decompensated Heart failure

BMAD TX - Benefits of uCor in Ambulatory Decompensated Heart failure

Principle Investigator: Robert Mohapatra, M.D.

Contact for Participation in this study:
Kristin Broderick
Research Assistant
856-673-1332
kbroderick@virtua.org

Office Location:
Virtua Cardiology Cherry Hill
1 Brace Road
Cherry Hill, NJ08034